The Korea Health Industry Development Institute (KHIDI) announced Wednesday that it is openly recruiting companies to participate in the Korea Startup/Biopharma Acceleration Program 2023, which provides opportunities for Korean startups or biopharmaceutical companies to collaborate with Japanese pha
Gilead Sciences Korea is seeking insurance coverage of its new drug Trodelvy (ingredient: sacituzumab govitecan) for the treatment of triple-negative breast cancer (TNBC).Speaking at a press conference celebrating the launch of the drug at the Plaza Hotel on Tuesday, the company said that it is curr
HK inno.N's indigenously developed drug K-CAB (tegoprazan) has been recognized as an outstanding technology that has contributed to the development of the Korean industry. On Tuesday, HK inno.N announced that K-CAB, a new drug for gastroesophageal reflux disease (GERD), has been selected as an outst
SK chemicals said it reported sales of 296.3 billion won ($226.3 million) and an operating profit of 23.9 billion won ($18.3 million) in the third quarter. Compared to a year earlier, sales and operating profit decreased by 8.6 percent and 30.8 percent, respectively.By business division, the green c
Orum Therapeutics said it has agreed to transfer all rights on ORM-6151, an acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome treatment candidate, to Bristol Myers Squibb (BMS) in a $180 million deal.Under the accord, BMS will pay Orum Therapeutics an upfront fee of $100 million and
Roche Korea said Lunsumio (ingredient: mosunetuzumab), a CD20/CD3 bispecific antibody, has received approval from the Ministry of Food and Drug Safety to treat adult patients with recurrent or refractory follicular lymphoma (FL) who have undergone two or more systemic therapies.Lunsumio is the first
i-SENS reported an operating loss of 400 million won ($300,000) in the third quarter of 2023 due to one-time costs of 2.5 billion won for legal and financial expenses related to the acquisition of AgaMatrix, a U.S. blood glucose meter manufacturer, and costs to prepare for the launch of a continuous
Huons and Kakao Healthcare have joined hands to co-market Dexcom G7, a continuous glucose monitoring (CGM) device developed by Dexcom, with Kakao Healthcare.Under the contract, both parties aim to make Dexcom G7 the top-selling CGM device in Korea, and improve convenience for diabetes patients.The t
Chong Kun Dang Pharmaceutical (CKD Pharm), a Korean drugmaker, said it has signed a $1.3 billion deal with global pharmaceutical giant Novartis to license out a new drug candidate, CKD-510. On the news of the deal, CKD Pharm’s stock price rose nearly 20 percent on Monday.CKD Pharm said Monday in a p
Dong-A ST announced Friday that it has signed an agreement with the University of Massachusetts Chan Medical School (UMass) to collaborate on adenovirus-associated virus (AAV) gene therapy targeting chronic inflammatory diseases.Under the agreement, UMass will transduce genes into AAVs, and UMass an
MSD Korea said its 15-valent pneumococcal conjugate vaccine Vaxneuvance received approval from the Ministry of Food and Drug Safety on Tuesday.Vaxneuvance is the first pneumococcal vaccine to be authorized in Korea in 13 years and has expanded its preventative range by adding two serotypes, 22F and
Maxigesic IV (acetaminophen-ibuprofen), a non-narcotic combined injection of analgesics Kyongbo Pharmaceutical exclusively sells in Korea, recently received new drug approval from the U.S. Food and Drug Administration based on clinical results showing it effectively reduces pain compared to single d
Biogen Korea is strengthening its position in the local spinal muscular atrophy (SMA) market with expanded reimbursement benefit of Spinraza (ingredient: nusinersen), the company said Thursday.Biogen Korea held a press conference at the Conrad Hotel in Yeouido, Seoul, Thursday, to commemorate the ex
In the midst of growing interest in ribonucleic acid (RNA)-based therapies, such as Spinraza (sodium nusinersenate) for spinal muscular atrophy (SMA) and the messenger ribonucleic acid (mRNA) Covid-19 vaccine, a Korean company is trying to become the industry's No. 1 contract manufacturing organizat
Over the past year, 33 global pharmaceutical companies conducted 1,600 clinical trials in Korea, investing over 800 billion won ($596.1 million) in research costs. The amount was up 14.3 percent, compared to a year earlier.The 14.3 percent R&D growth in 2022 was slower than that of 2021, which stood
Handok Pharmaceuticals, which entered the anticancer market for the first time this year, has begun laying the groundwork for a soft landing of its new cancer drugs in Korea.Handok is reportedly running a patient support program to support drug costs for acute myeloid leukemia drug Vyxeos (cytarabin
Helixmith, a Korean biotech firm focusing on gene therapy, is facing potential administrative measures from the Korea Exchange, having repeatedly delayed its capital increase payment deadlines over a span of six months.According to the Financial Supervisory Service's electronic disclosure system, th
The sudden proliferation of bed bugs in cities such as Daegu and Incheon has now reached Seoul, a capital with a population of 9.7 million people, and this is leading to a surge in demand for insect repellents.According to Dongsung Pharmaceutical, sales of their repellent Biokill in October have sky
Hanmi Pharm's cumulative sales in the first nine months of 2023 posted a record high of 1.1 trillion won ($810 million) on the back of robust prescription drug sales growth, the company said on Wednesday.If this revenue growth trend continues, the company’s annual sales are expected to set a new hig
iNtRON Biotechnology said it has signed a conditional license agreement with Basilea Pharmaceutical, a Switzerland-based multinational pharmaceutical company, prior to the main technology transfer agreement for SAL200, iNtRON's antibacterial bio-drug candidate. iNtRON had signed a technology transfe